News

News and Press Releases
Research | About the CF Foundation | Our Research Approach CF Foundation Awards Contract to Life Edit Therapeutics to Explore Gene Editing Technology in CF

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.

| 3 min read
Research | About the CF Foundation CF Foundation Commits up to $14 Million in Funding to Expand Research Agreement With Synspira Therapeutics

New funding will support clinical development of two novel therapies to address complications of cystic fibrosis

| 3 min read
Get Involved | About the CF Foundation CF Foundation Announces 2021 Impact Grant Recipients

The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.

| 5 min read
About the CF Foundation Cystic Fibrosis Foundation Announces Changes on Board of Trustees

Foundation welcomes new members to advance its mission

| 7 min read
About the CF Foundation | Our Research Approach CF Foundation Launches New Collaboration to Overcome Challenges to Developing Genetic Therapies for CF

Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.

| 4 min read
Research | About the CF Foundation | Clinical Trials CF Foundation Awards Up to $2M to Eloxx for Additional Support for Studies into Nonsense Mutations Therapy

Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative

New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations

| 5 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Invests Up to $8.4M in SpliSense for the Development of Potential Rare Mutation Therapy

Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.

| 4 min read
Advocacy | About the CF Foundation CF Foundation Responds to NIH Call for Information on Diversity and Inclusion

The Cystic Fibrosis Foundation recently submitted comments to the National Institutes of Health on improving racial equity, diversity, and inclusion in the biomedical research workforce.

| 2 min read